Sydney’s Transcranial Magnetic Stimulation (TMS) Treatment for Depression
What is Transcranial Magnetic Stimulation (TMS)?
TMS is Transcranial Magnetic Stimulation. It is a non-invasive, painless and effective treatment for depression. It uses precise pulsed magnetic fields to target and stimulate the prefrontal cortex of the brain involved in mood regulation with minimal side effects. Repeated activation of the left prefrontal cortex is proven to effectively relieve depression and help patients enjoy their lives both at work and with family and friends.
One of our TMS clinicians from our TMS care team will be with you the whole time you are having treatment and you can stop at any time. Our TMS care team deliver Transcranial Magnetic Stimulation depression treatment in friendly professional clinics in your Sydney community, including in Castle Hill, Kellyville, Pymble and northshore of Sydney.
We have now just launched our first TMS Australia clinic in Melbourne.
Founders of TMS Australia
About Paul Fitzgerald
Professor Paul Fitzgerald is Deputy Director of MAPrc, Professor of Psychiatry, and Consultant Psychiatrist at Alfred Psychiatry. He is a qualified psychiatrist, has a Masters of Psychological Medicine and research PhD.
Prof Paul Fitzgerald area of interest is brain stimulation and neuroimaging techniques. He is the leading expert in transcranial magnetic stimulation where he has conducted research with TMS for 18 years and has run the largest clinical TMS program in Australia for over 14 years. He has conducted more than 15 clinical trials evaluating brain stimulation treatment methods and has published over 300 journal articles and book chapters.
Paul’s view on TMS is
“We are currently seeing a shift in the way depression is being treated in Australia and around the world. The development of TMS provides us access to a very well tolerated, safe and very effective treatment for a substantial proportion of patients with depression. TMS is especially useful in the large group of patients who have not responded to, or can’t tolerate, medication therapies. TMS can make a real difference to the lives of many patients with depression and their family and friends”
Professor Fitzgerald was an elected board Member of the International Society for Transcranial Magnetic Stimulation (ISTS) and was an invited member of the World Federation of Biological Psychiatry Taskforce on Brain Stimulation (2006-2009). He is currently a committee member for the Electroconvulsive Therapy and Neurostimulation Special Interest Group with The Royal Australian and New Zealand College of Psychiatrists, and serves on the board of directors for Neurosciences Victoria. He is Psychiatric deputy editor for the journal ‘Brain Stimulation’ and is on the Editorial Boards of ‘Psychiatry Research’ and the ‘Australian and New Zealand Journal of Psychiatry’. He was awarded a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award in 2003 and 2005 and the Australasian Society for Psychiatric ResearchEli Lily Oration in 2012.
In addition he leads the MAPrC which is the primary training organisation for Psychiatrists and TMS Clinicians to be trained in the delivery of TMS
Great results, success and confidence has been delivered to patients and family at TMS Australia with Professor Fitzgerald leading up the clinics.
About Dr Ted Cassidy
What drives Dr Ted Cassidy are the great people and families he has worked with in his 15 years as a psychiatrist. Ted is an innovator, pioneer and founder of new services for the mentally ill. At TMS Australia, Ted and the TMS care team are using the next generation of technology to help people find their way back to happiness.
Dr Ted Cassidy founded The Hills Clinic in 2004. The Hills Clinic in Sydney has since become the leading private provider of conventional hospital and outpatient mental health care in north western Sydney with a team of more than 100 staff and clinicians. During Ted Cassidy’s leadership, over 15,000 people received care for mental illness to help them find their way back to happiness.
At TMS Australia, Dr Ted Cassidy hopes to explore the rich field of emerging technology in the treatment of mental illness and move beyond the conventional paradigm.
Dr Ted Cassidy has sought out leaders in the field of Transcranial Magnetic Stimulation: Monash Alfred Psychiatry Research Centre and Black Dog Institute, to help bring this leading edge technology to accessible clinics in your community.
Dr Ted Cassidy is a long standing supporter of Lifeline and joins Lifeline’s commitment to make effective treatments accessible for the mentally ill and their families.
Questions and Answers
Patients are awake and alert throughout.
Each treatment takes apprpximately 40 minutes. In this time, refresments such as tea and coffee will be offered, along with relaxing music and magazines. Alternatively. patients can sit or rest quietly. This is administered 3 to 5 days a week for approximately 4 to 6 weeks. Patients can go back to their normal activities immediately following.
Transcranial Magnetic Stimulation was first developed in 1985, and after undergoing research, it has been used to treat depression for the last 20 years. There do not appear to be any long term risks associated with TMS.
The most common side effects you can expect are headache and superficial scalp discomfort near where the TMS machine is placed. These are minor and it is rare for people to need to stop treatment. If headaches are experienced, they seem to occur less frequently as you get used to the treatment. There is also a rare risk of seizure, where statistics suggest that 1 in 30,000 treatments may experience a seizure.
Your nurse will carefully monitor you to ensure that you don’t have any problems.
TMS uses magnetic fields, so if you have any metal implants, or electronic medical devices above your chest and near the head region (e.g. cochlear implant, vagus nerve stimulators), you are not suitable for treatment.
Additionally there are limited studies on patients under 18 and pregnancy. However at TMS Australia we will continue to monitor research in younger and pregnant patients.